Kronos Bio (KRON) Stock Price, News & Analysis

Company Overview

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Key Stats

• Today's Range: $0.87 to $0.88
• 50-Day Range: $0.67 to $0.89
• 52-Week Range: $0.65 to $1.46
• Volume: 54,089 shs
• Average Volume: 370,931 shs
• Market Capitalization: $53.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.63
• Consensus Rating: Hold

KRON Stock Analysis - Frequently Asked Questions

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) issued its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.13. The business had revenue of $2.27 million for the quarter, compared to the consensus estimate of $1 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.22% and a negative net margin of 701.53%.

When did Kronos Bio IPO?

Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

What other stocks do shareholders of Kronos Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD).

Company Calendar

• Last Earnings: 3/18/2025
• Today: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRON
• CIK: 1741830
• Web: kronosbio.com
• Phone: 650-781-5200
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kronos Bio: $1.63
• High Price Target: $2.25
• Low Price Target: $1.00
• Potential Upside/Downside: +84.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.08 million
• Net Margins: -701.53%
• Pretax Margin: -701.53%
• Return on Equity: -64.22%
• Return on Assets: -47.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.93
• Quick Ratio: 12.93

Sales & Book Value

• Annual Sales: $9.85 million
• Price / Sales: 5.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.45 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 61,050,000
• Free Float: 46,155,000
• Market Cap: $53.72 million
• Optionable: Optionable
• Beta: 1.64